The work of the CGT facility will span across multiple things - from boosting immune responses against cancer to ensuring that therapeutic proteins are safely accepted in patients with genetic diseases like haemophilia
The findings, published in the journal Nature Communications, investigates the use of agenT-797, MiNK Therapeutic's allogeneic, unmodified invariant natural killer T (iNKT) cell therapy.
